In the BioHarmony Drug Report Database

"Preview" Icon

Inotuzumab ozogamicin

Besponsa (inotuzumab ozogamicin) is an antibody pharmaceutical. Inotuzumab ozogamicin was first approved as Besponsa on 2017-06-28. It is used to treat precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma. The pharmaceutical is active against B-cell receptor CD22.

 

Trade Name

 

Besponsa
 

Common Name

 

inotuzumab ozogamicin
 

ChEMBL ID

 

CHEMBL2108611
 

Indication

 

precursor cell lymphoblastic leukemia-lymphoma
 

Drug Class

 

Monoclonal antibodies: humanized, tumors as target; antibiotics (Micromonospora strains)

Image (chem structure or protein)

Inotuzumab ozogamicin structure rendering